Gland Pharma Limited

BSE: GLAND543245ISIN INE068V01023

Healthcare
Pharmaceuticals
BSE 500

BSE listing

Share price

₹2,961.90+51.25 (+1.76%)

as of 18 Sep 2026

52W high: ₹3,041.95
52W low: ₹1,575.00
Off 52W high: -2.63%
1M return: +4.20%
3M return: +34.75%
6M return: +82.25%
1Y return: +46.82%
20D avg volume: 6,27,194
50 DMA: ₹2,723.67
200 DMA: ₹2,094.39

Key ratios Consolidated

Market cap: ₹48,861 Cr
Current price: ₹2,961.90
52W high / low: ₹3,041.95 / ₹1,575.00
Face value: ₹1.00
P/E: 43.28
P/B: —
EPS (TTM): ₹68.43
Book value / share: —
ROE: —
ROCE: 13.70%
Operating margin: —
Net margin: —
Debt / equity: 0.02
Net debt: ₹-3,116 Cr
Interest cover: 45.01
Dividend yield: 0.68%
Dividend / share (TTM): ₹20.00
Payout: 29.23%
Cash conversion cycle: 159.1 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	1,800	1,743	1,695	1,487	1,506	1,425	1,384	1,406	1,402	1,537	1,545	1,373
	61.23	111.47	63.17	84.16	57.53	44.03	58.49	59.66	51.43	42.15	37.39	53.16
	1,427	1,348	1,372	1,287	1,250	1,181	1,143	1,209	1,235	1,281	1,299	1,137
	588.20	594.07	529.89	558.43	557.36	587.57	437.38	485.88	461.65	574.69	464.00	517.92
	1.95	2.28	1.50	1.94	0.88	3.10	2.15	2.66	6.58	6.76	6.38	6.13
	444.00	411.57	424.20	385.03	408.04	373.37	342.86	329.81	355.53	351.61	345.33	304.95
	4.36	10.03	3.93	7.82	11.50	7.45	22.82	6.11	5.62	9.96	5.28	6.05
	111.26	108.66	107.64	106.31	101.05	95.76	96.33	93.83	91.96	92.61	105.34	81.30
	242.58	226.87	259.64	234.15	208.69	216.07	163.87	158.13	171.01	169.93	180.16	164.55
	434.98	505.80	386.47	283.92	312.74	288.33	299.30	256.78	218.25	298.23	283.16	289.89
	0.00	0.00	-24.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	434.98	505.80	362.13	283.92	312.74	288.33	299.30	256.78	218.25	298.23	283.16	289.89
	118.02	139.12	100.65	100.23	97.26	101.79	94.61	93.25	74.48	105.81	91.30	95.81
	316.96	366.68	261.48	183.68	215.48	186.54	204.69	163.53	143.76	192.42	191.86	194.08
	19.23	22.26	15.87	11.15	13.08	11.32	12.42	9.93	8.73	11.68	11.65	11.78
Key metrics
	550.60	624.49	473.70	398.05	425.29	391.54	418.45	356.72	315.83	400.80	393.78	377.24
	30.60%	35.80%	27.90%	26.80%	28.20%	27.50%	30.20%	25.40%	22.50%	26.10%	25.50%	27.50%
	17.60%	21.00%	15.40%	12.40%	14.30%	13.10%	14.80%	11.60%	10.30%	12.50%	12.40%	14.10%
	—	4.70%	—	2.90%	—	3.10%	—	—	—	—	—	—
	19.60%	22.30%	22.50%	5.80%	7.40%	-7.30%	-10.40%	2.40%	—	—	—	—
	47.10%	96.60%	27.70%	12.30%	49.90%	-3.10%	6.70%	-15.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21
Income statement
	6,725	6,431	5,616	5,665	3,625	4,401	3,463
	320.03	316.33	213.61	170.24	240.46	223.94	134.78
	5,434	5,258	4,767	4,702	2,754	3,006	2,263
	2,271	2,240	1,972	2,022	1,717	2,047	1,749
	7.67	6.60	14.49	23.07	15.59	25.66	16.20
	1,665	1,629	1,402	1,257	403.26	338.57	311.36
	26.14	33.28	42.00	26.20	7.45	5.24	3.41
	433.87	423.67	377.87	344.57	146.74	110.30	98.78
	963.24	929.34	855.64	671.68	386.31	347.72	282.83
	1,611	1,489	1,063	1,133	1,111	1,619	1,335
	-24.35	-24.35	0.00	0.00	-56.46	0.00	0.00
	1,587	1,465	1,063	1,133	1,055	1,619	1,335
	458.02	437.26	364.13	360.08	273.54	406.89	337.85
	1,129	1,027	698.53	772.46	781.04	1,212	996.96
	68.51	62.35	42.40	46.90	47.44	73.81	63.07
Key metrics
	2,047	1,922	1,483	1,503	1,209	1,734	1,437
	30.43%	29.90%	26.40%	26.50%	33.30%	39.40%	41.50%
	16.78%	16.00%	12.40%	13.60%	21.50%	27.50%	28.80%
	—	13.70%	11.40%	—	—	—	—
	—	14.50%	-0.90%	56.30%	-17.60%	27.10%	—
	—	47.10%	-9.60%	-1.10%	-35.50%	21.50%	—
	—	540.63	530.19	—	—	—	—
	—	1.00	1.31	—	—	—	—
	—	0.02	0.03	—	—	—	—
	—	-3,116	-2,287	—	—	—	—
	—	159.1	154.8	—	—	—	—
Balance sheet
	—	12,511	11,225	—	—	—	—
	—	7,527	6,783	—	—	—	—
	—	3,359	2,556	—	—	—	—
	—	1,891	1,517	—	—	—	—
	—	1,744	1,685	—	—	—	—
	—	458.67	531.36	—	—	—	—
	—	4,052	3,751	—	—	—	—
	—	833.87	820.41	—	—	—	—
	—	1,608	1,565	—	—	—	—
	—	243.36	269.21	—	—	—	—
	—	173.44	191.55	—	—	—	—
	—	69.92	77.66	—	—	—	—
	—	10,358	9,151	—	—	—	—
Cash flow
	—	1,031	914.73	—	—	—	—
	—	137.73	1,705	—	—	—	—
	—	-416.97	-433.48	—	—	—	—
	—	490.76	384.54	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	1,287	1,262	1,178	1,074	1,039	1,030	1,011	1,063	1,012	1,175	1,098	1,011
	58.82	106.36	60.21	82.59	54.74	43.72	65.06	57.80	48.49	46.95	43.39	41.11
	857.77	803.15	800.92	748.07	731.19	682.75	681.72	740.98	760.20	789.10	769.50	704.72
	469.45	460.96	434.85	459.59	439.82	469.39	348.91	399.87	367.69	482.88	378.43	456.62
	1.95	2.28	1.50	1.94	0.88	3.10	2.15	2.67	6.58	6.83	6.38	6.13
	143.91	133.96	134.14	132.28	128.44	119.69	105.36	106.29	107.68	107.87	99.29	99.88
	0.69	6.17	0.50	3.97	7.43	3.45	18.31	0.17	0.91	4.53	0.80	0.91
	43.95	43.11	44.53	44.84	43.77	43.07	43.77	41.62	40.82	42.56	40.33	40.24
	161.97	135.13	157.46	147.38	125.07	111.32	105.43	92.55	102.86	88.55	111.95	93.16
	487.69	564.80	436.80	408.67	362.38	391.32	394.13	379.82	300.31	432.69	371.75	347.06
	0.00	0.00	-24.35	0.00	0.00	0.00	—	—	—	—	—	—
	487.69	564.80	412.46	408.67	362.38	391.32	394.13	379.82	300.31	432.69	371.75	347.06
	123.30	144.35	104.61	106.68	93.12	101.32	99.01	98.11	77.39	111.28	94.95	89.54
	364.39	420.45	307.85	302.00	269.26	290.00	295.12	281.71	222.92	321.41	276.81	257.53
	22.11	25.52	18.68	18.33	16.34	17.60	17.91	17.10	13.53	19.51	16.81	15.64
Key metrics
	532.33	614.08	457.49	457.48	413.58	437.84	456.21	421.61	342.04	479.78	412.88	388.21
	41.40%	48.70%	38.90%	42.60%	39.80%	42.50%	45.10%	39.70%	33.80%	40.80%	37.60%	38.40%
	28.30%	33.30%	26.10%	28.10%	25.90%	28.10%	29.20%	26.50%	22.00%	27.40%	25.20%	25.50%
	—	5.20%	—	4.00%	—	4.00%	—	—	—	—	—	—
	23.90%	22.40%	16.50%	1.00%	2.70%	-12.30%	-7.90%	5.20%	—	—	—	—
	35.30%	45.00%	4.30%	7.20%	20.80%	-9.80%	6.60%	9.40%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21
Income statement
	4,800	4,552	4,116	4,167	3,617	4,401	3,463
	307.98	303.90	215.07	166.67	240.46	223.94	134.78
	3,210	3,083	2,866	2,929	2,752	3,006	2,263
	1,825	1,795	1,586	1,710	1,717	2,047	1,749
	7.67	6.60	14.49	23.14	15.59	25.66	16.20
	544.29	528.82	439.02	409.94	399.70	338.57	311.36
	11.33	18.07	22.84	7.84	7.41	5.24	3.41
	176.43	176.24	169.27	162.11	146.74	110.30	98.78
	601.94	565.04	503.91	411.20	388.01	347.23	282.79
	1,898	1,773	1,466	1,406	1,105	1,619	1,335
	-24.35	-24.35	0.00	—	-56.46	—	—
	1,874	1,748	1,466	1,406	1,048	1,619	1,335
	478.94	448.76	375.83	362.17	272.58	406.89	337.85
	1,395	1,300	1,090	1,043	775.83	1,212	997.00
	84.64	78.88	66.15	63.35	47.12	73.84	63.07
Key metrics
	2,061	1,943	1,658	1,575	1,203	1,735	1,437
	42.95%	42.70%	40.30%	37.80%	33.30%	39.40%	41.50%
	29.06%	28.50%	26.50%	25.00%	21.50%	27.50%	28.80%
	—	16.10%	15.00%	—	—	—	—
	—	10.60%	-1.20%	15.20%	-17.80%	27.10%	—
	—	19.30%	4.40%	34.50%	-36.00%	21.60%	—
	—	917.30	938.56	—	—	—	—
	—	0.87	0.99	—	—	—	—
	—	0.00	0.00	—	—	—	—
	—	-3,178	-2,430	—	—	—	—
	—	184.4	178.3	—	—	—	—
Balance sheet
	—	11,607	10,422	—	—	—	—
	—	6,422	5,767	—	—	—	—
	—	3,178	2,433	—	—	—	—
	—	1,521	1,143	—	—	—	—
	—	1,265	1,254	—	—	—	—
	—	384.98	443.68	—	—	—	—
	—	1,684	1,736	—	—	—	—
	—	485.37	385.87	—	—	—	—
	—	633.02	523.76	—	—	—	—
	—	0.00	2.55	—	—	—	—
	—	0.00	1.44	—	—	—	—
	—	0.00	1.11	—	—	—	—
	—	10,810	9,755	—	—	—	—
Cash flow
	—	1,135	1,074	—	—	—	—
	—	-95.56	1,578	—	—	—	—
	—	-316.18	-339.54	—	—	—	—
	—	217.93	135.11	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +7.97%
Sales CAGR 5Y: +5.62%
Sales CAGR 10Y: —
Profit CAGR 3Y: +18.76%
Profit CAGR 5Y: +5.44%
Profit CAGR 10Y: —
Sales YoY (TTM): +15.86%
Profit YoY (TTM): +22.76%

Consolidated

Sales CAGR 3Y: +21.06%
Sales CAGR 5Y: +13.18%
Sales CAGR 10Y: —
Profit CAGR 3Y: +9.57%
Profit CAGR 5Y: +0.60%
Profit CAGR 10Y: —
Sales YoY (TTM): +17.57%
Profit YoY (TTM): +46.55%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 51.77%

Holder	Type	Holding	Previous	Change
Fosun Pharma Industrial Pte. Ltd	Promoter	51.77%	—	—
Hdfc Mutual Fund - Hdfc Mid-Cap Fund	Public	6.11%	—	—
Mirae Asset Large & Midcap Fund	Public	5.69%	—	—
Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund	Public	4.93%	—	—
Sbi Large & Midcap Fund	Public	3.32%	—	—
Icici Prudential India Opportunities Fund	Public	1.79%	—	—
Dsp Small Cap Fund	Public	1.62%	—	—
Government Pension Fund Global	Public	1.34%	—	—
Uti-Flexi Cap Fund	Public	1.22%	—	—
Lustrous Star Limited	Promoter Group	0.00%	—	—
Regal Gesture Limited	Promoter Group	0.00%	—	—
Fosun Industrial Co Limited	Promoter Group	0.00%	—	—
Ample Up Limited	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Acquisition of Gland Pharma USA Inc., a wholly-owned Step down subsidiary from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company13 Sep 2026 · Company Update / Acquisition
Outcome of Board Meeting13 Sep 2026 · Others / Outcome without intimation
Allotment of 44,193 Equity Shares on exercise of ESOPs13 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Grant of Stock Options under Gland Pharma Employee Stock Option Scheme, 202513 Sep 2026 · Company Update / General
Board Comments on fines levied by Exchanges13 Sep 2026 · Company Update / General
Schedule of Investor Meetings10 Sep 2026 · Company Update / Analyst / Investor Meet
Investor Meet Intimation8 Sep 2026 · Company Update / Analyst / Investor Meet
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Fosun Pharma Industrial Pte Ltd8 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Schedule of Investor Meet Intimation4 Sep 2026 · Company Update / Analyst / Investor Meet
Conclusion of USFDA Inspection at Company''s Facilities situated at Visakhapatnam1 Sep 2026 · Company Update / General
Schedule of Investor Meets31 Aug 2026 · Company Update / Analyst / Investor Meet
48th AGM Voting Results along with Scrutinizers Report26 Aug 2026 · AGM/EGM / AGM
48th AGM Outcome25 Aug 2026 · AGM/EGM / AGM
Schedule of Investor Meet23 Aug 2026 · Company Update / Analyst / Investor Meet
Q1FY27 Earnings Call Transcript17 Aug 2026 · Company Update / Earnings Call Transcript
Appointment of Chief Executive Officer of the Company14 Aug 2026 · Company Update / Change in Management
Newspaper Publication on Q1FY27 Financial Results11 Aug 2026 · Company Update / Newspaper Publication
Q1FY27 Earnings Call Audio recording10 Aug 2026 · Company Update / Analyst / Investor Meet
Schedule of Investor Meets10 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation on Q1FY27 Financial Results10 Aug 2026 · Company Update / Investor Presentation
Press release on Q1FY27 Financial Results10 Aug 2026 · Company Update / Press Release / Media Release
Outcome of Board Meeting10 Aug 2026 · Board Meeting / Outcome of Board Meeting
Unaudited Financial results for the quarter ended June 30, 202610 Aug 2026 · Result / Financial Results
Gland Pharma announces strategic CDMO partnership with a Global Pharmaceutical Company9 Aug 2026 · Company Update / Press Release / Media Release
Gland Pharma announces strategic collaboration with Neuland Laboratories for sterile API Manufacturing5 Aug 2026 · Company Update / Press Release / Media Release
Copy of News paper Publication1 Aug 2026 · Company Update / Newspaper Publication
Letter to Shareholders regarding dispatch of 48th AGM Notice and Annual report for the FY 2025-2631 Jul 2026 · Company Update / General
BRSR Report for the year ended March 31, 202631 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the FY 2025-2631 Jul 2026 · Others / Reg. 34 (1) Annual Report
Notice of 48th AGM31 Jul 2026 · AGM/EGM / AGM
Allotment of Equity Shares under ESOPS30 Jul 2026 · Company Update / Allotment of ESOP / ESPS
Grant of Stock Options under Gland Pharma Employee Stock Option Scheme, 202530 Jul 2026 · Company Update / Issue of Securities
Gland Pharma receives approval for Suggamadex Injection29 Jul 2026 · Company Update / Press Release / Media Release
Copy of News Paper Publication28 Jul 2026 · Company Update / Newspaper Publication
Q1FY27 Earnings Call Intimation24 Jul 2026 · Company Update / Analyst / Investor Meet
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Unaudited Standalone and Consolidated ....24 Jul 2026 · Board Meeting / Board Meeting
Reappointment of Mr. Vetter and Appointment of Mr. Keller as Independent Directors of the Company20 Jul 2026 · Company Update / Change in Directorate
Scrutinizers Report on the Postal Ballot20 Jul 2026 · AGM/EGM / Postal Ballot
Postal Ballot Outcome20 Jul 2026 · AGM/EGM / Postal Ballot
Intimation of Order passed by the Customs Authority16 Jul 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 20.0000	11 Aug 2026	11 Aug 2026	—
Final Dividend - Rs. - 18.0000	14 Aug 2025	14 Aug 2025	—
Final Dividend - Rs. - 20.0000	16 Aug 2024	16 Aug 2024	—

Board meetings

10 Aug 2026 Board Meeting - Financial Results